Skip to main content

Generics

  • FDA approves Endo generic Plendil

    CHADDS FORD, Pa. — The Food and Drug Administration has approved a drug made by Endo Pharmaceuticals for high blood pressure.

    Endo announced Wednesday the approval of felodipine extended-release tablets in the 2.5-mg, 5-mg and 10-mg strengths. Endo's generic drugs division, Qualitest Pharmaceuticals, will manufacture and distribute the product.

    The drug is a generic version of AstraZeneca's Plendil extended-release tablets. Felodipine had sales of about $84 million during the 12-month period ended in June, according to IMS Health.

  • Perrigo seeks approval for generic version of Abbott's Androgel

    ALLEGAN, Mich. — Drug maker Perrigo has filed for regulatory approval of a generic topical drug for treating testosterone deficiency, prompting a patent infringement suit from the branded version's manufacturer.

  • Impax reports sales, profit increases in third quarter

    HAYWARD, Calif. — Drug maker Impax Labs reported sales of $119.8 million and profits of $20 million in third quarter 2011, according to an earnings report released Tuesday.

    The latest sales figures represented a $12.2 million increase over third quarter 2010, while profits were $4.2 million higher.

  • Watson sales, profits surge in Q3

    PARSIPPANY, N.J. — Watson Pharmaceuticals had sales of $1.1 billion and profits of $68.1 million in third quarter 2011, the drug maker said in an earnings statement Tuesday.

    The latest figures compared with sales of $882.4 million and profits of $25.7 million in third quarter 2010, the company said. For the first nine months of 2011, sales were $3.04 billion and profits were $166.1 million, compared with sales of $2.61 billion and profits of $166.1 million in the first nine months of 2010.

  • Pfizer could lose No. 1 global sales ranking to Sanofi next year, report finds

    LONDON — Pfizer soon may lose its distinction of having the highest global sales of any drug company, according to life sciences industry analysis firm EvaluatePharma.

    The next contender for the title is France's Sanofi, which EvaluatePharma said was expected to take the top spot next year and stay there through 2016.

  • Obama issues executive order to address drug shortages

    WASHINGTON — President Barack Obama issued an executive order Monday to address the growing problem of drug shortages.

  • Court injunction stops Watson, Amphastar from marketing, selling Lovenox generic

    PARSIPPANY, N.J. — Watson Pharmaceuticals and a partnering company are barred from launching a generic version of a blood-thinning drug under a federal court decision issued Friday.

  • Endo to move HQ in 2012

    CHADDS FORD, Pa. — Endo Pharmaceuticals announced it will move its corporate headquarters to a new facility by next December.

    The new corporate center will be located in Malvern, Pa., about 18 miles from its current location of Chadds Ford, Pa. Endo said the move reflects the company's continued growth.

    "This move is an important investment in Endo's future," Endo CEO Dave Holveck said. "I believe this move will undoubtedly send a positive message of growth, stability and promise to our pharmaceutical and business counterparts."

X
This ad will auto-close in 10 seconds